1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. INDIA PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE
5.1. Introduction
5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.3. Corticosteroids
5.4. Acetaminophen
5.5. Opioid
5.5.1. Strong Opioid
5.5.2. Weak Opioid
5.6. Antidepressants
5.7. Anticonvulsant Drugs
5.8. Others
6. INDIA PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL
6.1. Introduction
6.2. Hospital Pharmacies
6.3. Retail Pharmacies
6.4. Online Pharmacies
7. INDIA PAIN MANAGEMENT DRUGS MARKET BY INDICATION
7.1. Introduction
7.2. Cancer
7.3. Rheumatoid Arthritis
7.4. Chronic Back Pain
7.5. Post-Operative Pain
7.6. Others
8. INDIA PAIN MANAGEMENT DRUGS MARKET BY STATE
8.1. Introduction
8.2. Uttar Pradesh
8.2.1. By Drug Type
8.2.2. By Distribution Channel
8.2.3. By Indication
8.3. Maharashtra
8.3.1. By Drug Type
8.3.2. By Distribution Channel
8.3.3. By Indication
8.4. Madhya Pradesh
8.4.1. By Drug Type
8.4.2. By Distribution Channel
8.4.3. By Indication
8.5. West Bengal
8.5.1. By Drug Type
8.5.2. By Distribution Channel
8.5.3. By Indication
8.6. Rajasthan
8.6.1. By Drug Type
8.6.2. By Distribution Channel
8.6.3. By Indication
8.7. Others
8.7.1. By Drug Type
8.7.2. By Distribution Channel
8.7.3. By Indication
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Novartis Pharmaceuticals Corporation (Novartis AG)
10.2. Eli Lilly and Company
10.3. Pfizer Inc.
10.4. GlaxoSmithKline plc
10.5. Sanofi S.A
10.6. Viatris Inc.
10.7. Abbott Laboratories
10.8. Anglo-French Drugs & Industries Ltd.
10.9. Rusan Pharma
10.10. Cipla
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations